<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-id journal-id-type="hwp">ofids</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5782025</article-id><article-id pub-id-type="doi">10.1093/ofid/ofu051.98</article-id><article-id pub-id-type="publisher-id">ofu051</article-id><article-categories><subj-group subj-group-type="heading"><subject>IDWeek 2014 Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Oral Abstracts</subject></subj-group></subj-group></article-categories><title-group><article-title>1210<break/>A Phase 3, Randomized, Double-Blind, Non-inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Neutropenic Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Patterson</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="sa98-af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Selleslag</surname><given-names>Dominik</given-names></name><xref ref-type="aff" rid="sa98-af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mullane</surname><given-names>Kathleen</given-names></name><xref ref-type="aff" rid="sa98-af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cornely</surname><given-names>Oliver</given-names></name><xref ref-type="aff" rid="sa98-af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hope</surname><given-names>William</given-names></name><xref ref-type="aff" rid="sa98-af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lortholary</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="sa98-af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Zeiher</surname><given-names>Bernhardt</given-names></name><xref ref-type="aff" rid="sa98-af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Maher</surname><given-names>Rochelle</given-names></name><xref ref-type="aff" rid="sa98-af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Misun</given-names></name><xref ref-type="aff" rid="sa98-af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Wenmei</given-names></name><xref ref-type="aff" rid="sa98-af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Kontoyiannis</surname><given-names>Dimitrios</given-names></name><xref ref-type="aff" rid="sa98-af8">8</xref></contrib></contrib-group><aff id="sa98-af1"><label>1</label>The University of Texas Health Science Center, San Antonio, TX</aff><aff id="sa98-af2"><label>2</label>A.Z. Sint-Jan, Brugge, Belgium</aff><aff id="sa98-af3"><label>3</label>University of Chicago Medicine, Chicago, IL</aff><aff id="sa98-af4"><label>4</label>Uniklinik koln, Cologne, Germany</aff><aff id="sa98-af5"><label>5</label>Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom</aff><aff id="sa98-af6"><label>6</label>., Institut Pasteur, Paris, France</aff><aff id="sa98-af7"><label>7</label>Astellas Pharma Global Development, Northbrook, IL</aff><aff id="sa98-af8"><label>8</label>The University of Texas MD Anderson Cancer Center, Houston, TX</aff><author-notes><fn id="TN202" fn-type="con"><p><bold>Session:</bold> 148. Fungal Infections</p></fn><fn id="TN203" fn-type="con"><p>Friday, October 10, 2014: 2:00 PM</p></fn></author-notes><pub-date pub-type="ppub"><month>12</month><year>2014</year></pub-date><pub-date pub-type="epub" iso-8601-date="2014-12-01"><month>12</month><year>2014</year></pub-date><volume>1</volume><issue>Suppl 1</issue><issue-title>IDWeek 2014 Abstracts</issue-title><fpage seq="b">S36</fpage><lpage>S37</lpage><permissions><copyright-statement>&#x000a9; The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America</copyright-statement><copyright-year>2014</copyright-year></permissions><self-uri xlink:href="ofu051.98.pdf"/></article-meta></front><body><p><bold><italic>Background.</italic></bold>&#x02003;Isavuconazole (ISA) is a novel, broad-spectrum, triazole antifungal available as a water-soluble prodrug in IV and oral formulations for treatment of invasive fungal disease. A Phase 3 trial (NCT00412893) assessed the efficacy and safety of ISA vs voriconazole (VRC) in patients with invasive mold disease (IMD). Neutropenia is linked to significant morbidity and mortality in patients with IMD. We present outcomes in patients with and without neutropenia at baseline from this trial.</p><p><bold><italic>Methods.</italic></bold>&#x02003;Patients with proven/probable/possible IMD (EORTC/MSG criteria) were randomized 1:1 to receive ISA or VRC for up to 84 days. Dosing regimens were: ISA 200mg IV TID for 2 days, then 200mg QD (IV or PO); VRC 6mg/kg IV BID on Day 1, 4mg/kg IV BID on Day 2, then either 4mg/kg IV BID or 200mg PO BID. The primary endpoint was all-cause mortality through Day 42. Overall success at end-of-treatment (EOT) as determined by an independent data-review committee (DRC), safety, and tolerability were also analyzed. Neutropenia was defined as per EORTC/MSG criteria.</p><p><bold><italic>Results.</italic></bold>&#x02003;Patient characteristics, efficacy, and safety outcomes are shown in the table.</p><p><bold><italic>Conclusion.</italic></bold>&#x02003;ISA has comparable efficacy to VRC for the primary treatment of IMD in neutropenic and non-neutropenic patients and may be better tolerated.
</p><table-wrap id="OFU051TB22" orientation="portrait" position="float"><caption><p>Patient characteristics and outcomes</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th colspan="1" rowspan="1"/><th align="center" colspan="3" rowspan="1">Neutropenic<hr/></th><th align="center" colspan="3" rowspan="1">Non-neutropenic<hr/></th></tr><tr><th colspan="1" rowspan="1"/><th align="center" colspan="2" rowspan="1">ISA</th><th align="center" colspan="1" rowspan="1">VRC</th><th align="center" colspan="2" rowspan="1">ISA</th><th align="center" colspan="1" rowspan="1">VRC</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">All treated patients (ITT), n</td><td align="center" colspan="2" rowspan="1">163</td><td colspan="1" rowspan="1">175</td><td align="center" colspan="2" rowspan="1">94</td><td colspan="1" rowspan="1">84</td></tr><tr><td colspan="1" rowspan="1">Proven/probable IMD (mITT), n</td><td align="center" colspan="2" rowspan="1">88</td><td colspan="1" rowspan="1">73</td><td align="center" colspan="2" rowspan="1">55</td><td colspan="1" rowspan="1">56</td></tr><tr><td colspan="1" rowspan="1"><italic>Efficacy</italic></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">ISA n (%)</td><td colspan="1" rowspan="1">VRC n (%)</td><td colspan="1" rowspan="1">Adjusted difference* % (95% CI)</td><td colspan="1" rowspan="1">ISA n (%)</td><td colspan="1" rowspan="1">VRC n (%)</td><td colspan="1" rowspan="1">Adjusted difference* % (95% CI)</td></tr><tr><td colspan="1" rowspan="1">All-cause mortality Day 42</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;ITT</td><td colspan="1" rowspan="1">34 (21)</td><td colspan="1" rowspan="1">37 (21)</td><td colspan="1" rowspan="1">&#x02013;0.2 (&#x02013;8.7, 8.3)</td><td colspan="1" rowspan="1">14 (15)</td><td colspan="1" rowspan="1">15 (18)</td><td colspan="1" rowspan="1">&#x02013;4.0 (&#x02013;14.2, 6.2)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;mITT</td><td colspan="1" rowspan="1">22 (25)</td><td colspan="1" rowspan="1">17 (23)</td><td colspan="1" rowspan="1">2.4 (&#x02013;10.2, 14.9)</td><td colspan="1" rowspan="1">6 (11)</td><td colspan="1" rowspan="1">13 (23)</td><td colspan="1" rowspan="1">&#x02013;13.5 (&#x02013;26.8, &#x02013;0.3)</td></tr><tr><td colspan="1" rowspan="1">Overall success EOT</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;ITT</td><td colspan="1" rowspan="1">67 (41)</td><td colspan="1" rowspan="1">75 (43)</td><td colspan="1" rowspan="1">2.2 (&#x02013;8.3, 12.8)</td><td colspan="1" rowspan="1">24 (25)</td><td colspan="1" rowspan="1">23 (28)</td><td colspan="1" rowspan="1">1.0 (&#x02013;13.2, 15.2)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;mITT</td><td colspan="1" rowspan="1">34 (39)</td><td colspan="1" rowspan="1">29 (40)</td><td colspan="1" rowspan="1">0.4 (&#x02013;14.0, 14.7)</td><td colspan="1" rowspan="1">16 (29)</td><td colspan="1" rowspan="1">18 (32)</td><td colspan="1" rowspan="1">2.5 (&#x02013;13.3, 18.2)</td></tr><tr><td colspan="1" rowspan="1"><italic>Safety</italic></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">AEs, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;ITT</td><td align="center" colspan="2" rowspan="1">158 (97)</td><td colspan="1" rowspan="1">172 (98)</td><td align="center" colspan="2" rowspan="1">89 (95)</td><td colspan="1" rowspan="1">83 (99)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;mITT</td><td align="center" colspan="2" rowspan="1">85 (97)</td><td colspan="1" rowspan="1">71 (97)</td><td align="center" colspan="2" rowspan="1">53 (96)</td><td colspan="1" rowspan="1">55 (98)</td></tr><tr><td colspan="1" rowspan="1">Drug-related AEs, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;ITT</td><td align="center" colspan="2" rowspan="1">70 (43)</td><td colspan="1" rowspan="1">101 (58)</td><td align="center" colspan="2" rowspan="1">39 (42)</td><td colspan="1" rowspan="1">54 (64)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;mITT</td><td align="center" colspan="2" rowspan="1">35 (40)</td><td colspan="1" rowspan="1">41 (56)</td><td align="center" colspan="2" rowspan="1">22 (40)</td><td colspan="1" rowspan="1">38 (68)</td></tr></tbody></table><table-wrap-foot><fn id="TN204" fn-type="con"><p>*ISA&#x02013;VRC (VRC&#x02013;ISA for overall success)</p></fn><fn id="TN205" fn-type="con"><p>ITT, intent-to-treat population (patients who received &#x02265;1 dose of study drug); mITT, modified intent-to-treat population (patients in ITT with proven/probable IMD as assessed by DRC)</p></fn></table-wrap-foot></table-wrap><p><bold><italic>Disclosures.</italic></bold>&#x02003;<bold>T. Patterson</bold>, Astellas: Consultant and Scientific Advisor, Consulting fee <bold>D. Selleslag</bold>, Pfizer: Investigator and Speaker's Bureau, Educational grant, Research grant and Speaker honorarium; Astellas: Investigator, Research support <bold>K. Mullane</bold>, Astellas: Research Contractor and Speaker's Bureau, Research support; Pfizer: Research Contractor, Research support <bold>O. Cornely</bold>, Astellas: Investigator and Scientific Advisor, Consulting fee, Research grant and Speaker honorarium; Pfizer: Investigator and Scientific Advisor, Consulting fee, Research grant and Speaker honorarium; Basilea: Consultant and Investigator, Consulting fee and Research grant <bold>W. Hope</bold>, Astellas: Grant Investigator, Investigator and Scientific Advisor, Consulting fee, Grant recipient and Research grant; Pfizer: Grant Investigator, Consulting fee and Research support <bold>O. Lortholary</bold>, Astellas: Investigator, Research support; Pfizer: Speaker's Bureau, Speaker honorarium <bold>B. Zeiher</bold>, Astellas: Employee, Salary <bold>R. Maher</bold>, Astellas Pharma Global Development: Employee, Salary <bold>M. Lee</bold>, Astellas: Employee, Salary <bold>W. Huang</bold>, Astellas: Employee, Salary <bold>D. Kontoyiannis</bold>, Astellas: Investigator, Research grant and Research support; Pfizer: Investigator, Research grant and Speaker honorarium</p></body></article>